Oral Colon Cancer Agent as Effective as IV Regimen, Less Toxic

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

NOTTINGHAM, UK-In a phase III multinational study, UFT capsules (uracil/tegafur) in combination with leucovorin calcium tablets proved as effective as IV fluorouracil (5-FU)/leucovorin, and much less toxic, when used as first-line treatment of metastatic colorec-tal cancer, James Carmichael, MD, of Nottingham City Hospital, UK, reported at the 35th annual meeting of the American Society of Clinical Oncology in Atlanta. [The FDA’s Oncologic Drugs Advisory Committee has recommended that UFT capsules plus oral leucovorin be approved for advanced colorectal cancer; a complete report will appear next month.]

NOTTINGHAM, UK—In a phase III multinational study, UFT capsules (uracil/tegafur) in combination with leucovorin calcium tablets proved as effective as IV fluorouracil (5-FU)/leucovorin, and much less toxic, when used as first-line treatment of metastatic colorec-tal cancer, James Carmichael, MD, of Nottingham City Hospital, UK, reported at the 35th annual meeting of the American Society of Clinical Oncology in Atlanta. [The FDA’s Oncologic Drugs Advisory Committee has recommended that UFT capsules plus oral leucovorin be approved for advanced colorectal cancer; a complete report will appear next month.]

The study results are consistent with data from a similar multinational trial of UFT/leucovorin, reported by Richard Pazdur, MD, at the ASCO meeting .

Dr. Carmichael reported on 380 patients randomized to receive UFT (300 mg/m²/d) plus leucovorin (90 mg/d), both administered orally for 28 days every 35 days, or 5-FU (425 mg/m²/d) plus leucovorin (20 mg/m²/d), both given intravenously for 5 days every 35 days.

Efficacy was comparable between the two arms, he said. The median time to progression was 3.4 and 3.3 months, respectively, in the oral and IV regimens (P = .591); median survival times were 12.2 and 11.9 months (P = .682); and overall response rates were 11% and 9% (P = .593). However, UFT was associated with significant reductions in the incidence and severity of major side effects, compared with 5-FU/leucovorin. The incidence of grade 3-4 stomatitis/mucositis was 2% for the oral therapy vs 16% with 5-FU/leucovorin (P < .001), and the incidence of grade 3-4 neutropenia was 3% vs 31% (P < .001). The lower incidence of severe neutropenia with the oral therapy translated into significantly fewer episodes of febrile neutropenia (P < .001) and documented infection (P = .040).

Although the incidences of diarrhea and nausea and vomiting were similar between the two groups, use of concomitant medication, including antiemetics, was significantly higher in the 5-FU/leucovorin arm, Dr. Carmichael said.

“These results show that first-line oral outpatient treatment of metastatic colorectal cancer is viable and, in fact, represents a better tolerated, more convenient option for patients,” he concluded.

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Related Content